Design, Development, and Optimization of Spanlastics for Delivery of Rizatriptan Benzoate

Spanlastics are nanovascular drug delivery systems that use surfactants, including hydrophilic and hydrophobic medicines . Spanlastics enhance the ability of medicines to enter the body and provide a continuous release over extended periods . These vesicles possess a high degree of elasticity and flexibility , enabling to improve the transportation of medications through different methods of administrations . Box-behnken design was utilized to establish a relationship between the formulation parameters, specifically the amount of Span 60 , cremophor EL 40 and sonication time and important quality attributes , namely particle size , polydispersity index (PDI) and entrapment efficiency (EE%) . The spanlastic formulations were developed using response surface central composite design and formulated using an ethanol injection . The developed using response surface central composite design and formulated using an ethanol injection . The formulations were analyzed to identify the optimal formula with a tiny particle size , lower PDI and a high EE%. The optimized formula underwent additional analysis using zeta potential measurement in-vitro release profile , Fourier Transform Infrared (FTIR) Analysis , Field Emission Scanning Electron Microscopy (FESEM) ,Differential Scanning Calorimetry Analysis (DSC) and X-ray Diffraction Analysis (XRD) .The improved formulation exhibited a particle size of (84,98)nm, a PDI of 0.1993 and an EE% of (53.69)% . There is a little discrepancy between the observed and predicated values . The zeta potential was - 22. 37 . The optimum formula showed an appropriate release of 88.5% over 8 hr . The compatibility analysis demonstrated that RNB is compatible with the other excipients .Analysis of the vesicle shape revealed that it was nearly spherical . Furthermore , the drug molecule was seen to exist in an amorphous condition within spanlastic formula . In summary , the result demonstrated that spanlastic have the capacity to serve as a carrier for medicine delivery systems .